-
Mashup Score: 2Patent Issued for Methods of Identifying Patients With Substance Use-Associated Genetic Markers, Treatment With AD04 - 5 day(s) ago
A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 1Major Depressive Disorder Research Roundup: February 6, 2025 - 5 day(s) ago
Learn more about the latest research on the impact the endocrine system has on major depressive disorder.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 3AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment - 5 day(s) ago
A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 7Postpartum Depression (PPD) Patient Case Studies: Diagnostic Insights and Therapeutic Outcomes - 5 day(s) ago
Panelists discuss how the diagnostic challenges and treatment options for postpartum depression (PPD) are addressed through case studies, emphasizing the importance of early identification, personalized care, and the role of rapid-onset therapies like zuranolone in improving patient outcomes.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 5
New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 2Patent Issued for Methods of Identifying Patients With Substance Use-Associated Genetic Markers, Treatment With AD04 - 6 day(s) ago
A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 3Delays in Psychiatric Care: New Hampshire’s Robust Response - 7 day(s) ago
New Hampshire’s mental health system faces ongoing challenges with emergency department boarding, legal concerns over due process, and resource shortages, prompting reforms to improve patient care and access.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 9First Patient Dosed in Second Phase 3 Study of Psychedelic MM120 for Generalized Anxiety Disorder - 8 day(s) ago
MindMed has announced the dosing of the first patient in its second Phase 3 study of MM120.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 12A Love Letter to My Workplace: An Ethical Model of Private Practice for Clinician and Patient Well-Being - 8 day(s) ago
A clinician’s search for flexibility, autonomy, and ethical care leads her to a private practice that redefines work-life balance in medicine.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
-
Mashup Score: 0Clinical Pearls: Inside the Mind of the Athlete - 9 day(s) ago
With the Super Bowl highlighting elite athletic performance, sports psychiatry is essential in strengthening athletes’ mental resilience and well-being.
Source: www.psychiatrictimes.comCategories: General Medicine News, PsychiatryTweet
The United States Patent and Trademark Office has issued a patent for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04. https://t.co/cXQIAajWRM